Jasper Therapeutics’ stock has dropped after it announced it was investigating the impact of a faulty batch of its investigational antibody therapy dosed in a Phase Ib/IIa trial.

PulseSight Therapeutics has dosed the first subject in the Phase I trial of its first-in-class non-viral vectorised therapy, PST-611.

The FDA and the EMA have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib for mCRPC.

Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, for C3-glomerulopathy (C3G).

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.

Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

Tango has dosed the first subject in the Phase I/II trial of TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib.